Journal article
Contribution of cardiometabolic risk factors to estimated glomerular filtration rate decline in Indigenous Australians with and without albuminuria - the eGFR Follow-up Study
Elizabeth LM Barr, Federica Barzi, Jaquelyne T Hughes, George Jerums, Kerin O'Dea, Alex DH Brown, Elif I Ekinci, Graham RD Jones, Paul D Lawton, Ashim Sinha, Richard J MacIsaac, Alan Cass, Louise J Maple-Brown
NEPHROLOGY | WILEY | Published : 2018
DOI: 10.1111/nep.13073
Abstract
AIM: We assessed associations between cardiometabolic risk factors and estimated glomerular filtration rate (eGFR) decline according to baseline albuminuria to identify potential treatment targets in Indigenous Australians. METHODS: The eGFR Follow-up Study is a longitudinal cohort of 520 Indigenous Australians. Linear regression was used to estimate associations between baseline cardiometabolic risk factors and annual Chronic Kidney Disease Epidemiology Collaboration eGFR change (mL/min per 1.73m2 /year), among those classified with baseline normoalbuminuria (urine albumin-to-creatinine ratio (uACR) <3 mg/mmol; n = 297), microalbuminuria (uACR 3-30 mg/mmol; n = 114) and macroalbuminuria (uA..
View full abstractGrants
Awarded by National Health and Medical Research Council of Australia (NHMRC)
Awarded by NHMRC
Funding Acknowledgements
The authors gratefully acknowledge the support of the eGFR study participants, study staff and partner organizations. We thank Dr Kevin Warr and Dr William Majoni for facilitating participant recruitment and follow-up at the sites of their employing organization and Loyla Leysley, Sian Graham, Mary Ward and Joseph Fitz for assistance with follow-up in their communities. The authors also thank Melbourne Pathology for providing the technical support in the enzymatic creatinine analysis and Roche Diagnostics for supplying the enzymatic creatinine reagent kit for the baseline study. The eGFR study was funded by the National Health and Medical Research Council of Australia (NHMRC, Project Grants no. 545202 and no. 1021460), with additional support from Kidney Health Australia, NHMRC Program Grant (no. 631947), the Colonial Foundation, Diabetes Australia Research Trust, Rebecca L Cooper Foundation and SeaSwift, Thursday Island. ELMB was supported by an NHMRC Training Research Fellowship (APP1016612); LJM-B was supported by an NHMRC Fellowship (no. 605837) and NHMRC Practitioner Fellowship (no. 1078477); FB was supported by NHMRC Program Grant (no. 631947); JTH was supported by NHMRC Fellowship no. 1092576 and Royal Australian College of Physicians (RACP) Jacquot Research Establishment Award; PDL was supported by NHMRC Scholarship no. 1038721 and RACP Jacquot Research Establishment Award; EIE was supported by an NHMRC Early Career Fellowship: Health Professional Research Fellowship (Part Time, no. 1054312), Viertel Clinical Investigatorship and a RACP Juvenile Diabetes Research Foundation (JDRF) Research Establishment Fellowship. ADHB is supported by a Viertel Senior Medical Research Fellowship. RM was supported by an Australian Diabetes Society-Servier Diabetes Research Grant, Rebecca Cooper Medical Research Foundation and the St. Vincent's Hospital Melbourne Research Endowment Fund. The views expressed in this publication are those of the authors and do not reflect the views of the NHMRC. Funding bodies had no role in the study design, in the collection, analysis or interpretation of data, in the writing of the manuscript or the decision to submit the manuscript for publication.